Browse the corpus

Mannitol is FDA-approved for the reduction of intracranial pressure associated with cerebral edema and the reduction of intraocular pressure. Mannitol is also administered via inhalation as adjunctive therapy in cystic fibrosis. Additionally, it promotes diuresis in acute kidney injury, aiding in the prevention or treatment of the oliguric phase and facilitating the excretion of toxic substances and metabolites. This activity discusses mannitol's mechanism of action, adverse event profile, monitoring parameters, administration guidelines, clinical toxicology considerations, pharmacokinetic aspects, contraindications, and relevant interactions. Equipping healthcare professionals with this knowledge allows them to tailor treatment plans, optimize dosing strategies, and effectively manage adverse reactions, enhancing outcomes for patients with conditions managed with mannitol therapy. Objectives: Identify the FDA-approved indications for mannitol. Evaluate the mechanism of action of mannitol. Assess the adverse effects of mannitol. Strategies effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from mannitol therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Clinical features of overdose include hypervolemia/hypovolemia, hyperosmolarity, acute kidney injury, CNS toxicity-like coma or seizures, and electrolyte imbalances. Management of Overdose Management of mannitol injection overdose is primarily symptomatic and supportive. This management involves discontinuing the infusion and addressing fluid and electrolyte imbalances. Dialysis partially removes mannitol. Repeated doses of mannitol lead to the build-up of mannitol even with dialysis.[21]

An interprofessional team approach is optimal for mannitol administration. Monitoring cardiac function is essential as the fluid shifts can precipitate heart failure. Additional electrolytes, including sodium, potassium, and osmolality, require monitoring by the nurses and physicians. Abnormalities in these laboratory values necessitate prompt action from team members. Mannitol administration should stop if significant electrolyte abnormalities develop or the osmolality reaches 320 mOsm or higher. When mannitol treats cerebral edema, serum osmolality should be checked every 4 to 6 hours. If serum osmolality exceeds 320 mOsm, alternative agents like the hypertonic solution should be used.[20] Neurosurgery and neurocritical care consultation is indicated for cerebral edema cases. Pulmonology consultation is indicated for cystic fibrosis/asthma. The nursing staff should carefully monitor urine output, reporting concerns to the treating clinician. The pharmacist can verify dosing, perform medication reconciliation, and alert the team for potential interactions. They can also collaborate with the attending physician regarding potential alternative therapies in the event of therapeutic failure or mannitol intolerance. With open interprofessional communication between all healthcare team members, mannitol therapy has the best chance at optimal results. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists are necessary to optimize patient outcomes with mannitol therapy.